Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors

Clinical Journal of Oncology Nursing

Volumn 15, Issue 5, 2011, Pages 501-508

  Boucher, Jean ^a   Olson, Linnea ^a   Piperdi, Bilal ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

DRUG ANTAGONISM; DRUG ERUPTION; HUMAN; NEOPLASM; NURSING; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG ERUPTIONS; HUMANS; NEOPLASMS; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 80053276024     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/11.CJON.501-508     Document Type: Review

References (43)

1. Agero, A.L., Dusza, S.W., Benvenuto-Andrade, C., Busam, K.J., Myskowski, P., & Halpern, A.C. (2006). Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 55, 657-670.
2. Arteaga, C.L. (2001). The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. Journal of Clinical Oncology, 19(18, Suppl.), 32S-40S.
3. Avruch, J., Khokhlatchev, A., Kyriakis, J.M., Luo, Z., Tzivion, G., Vavvas, D., & Zhang, X.F. (2001). Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade. Recent Progress in Hormone Research, 56, 127-155.
4. Basti, S. (2007). Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nursing, 30(4, Suppl. 1), S10-S16. doi:10.1097/01.NCC.0000281759.23823.82
5. Bonner, J.A., Harari, P.M., Giralt, J., Azarnia, N., Shin, D.M., & Cohen, R.B. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 354, 567-578. doi:10.1056/NEJMoa053422
6. Bulgaru, A.M., Mani, S., Goel, S., & Perez-Soler, R. (2003). Erlotinib (Tarceva): A promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Review of Anticancer Therapy, 3, 269-279. doi:10.1586/14737140.3.3.269
7. Busam, K.J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A.C. (2001). Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. British Journal of Dermatology, 144, 1169-1176.
8. Downward, J. (2003). Targeting RAS signaling pathways in cancer therapy. Nature Reviews. Cancer, 3, 11-22. doi:10.1038/nrc969
9. Eaby, B., Culkin, A., & Lacouture, M.E. (2008). An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clinical Journal of Oncology Nursing, 12, 283-290. doi:10.1188/08.CJON.283-290
10. Finlay, A.Y., & Khan, G.K. (1994). Dermatology Life Quality Index (DLQI)-A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19, 210-216.
11. Fox, L.P. (2007). Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. Journal of the American Academy of Dermatology, 56, 460-465. doi:10.1016/j.jaad.2006.09.013
12. Galimont-Collen, A.F., Vos, L.E., Lavrijsen, A.P., Ouwerkerk, J., & Gelderblom, H. (2007). Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. European Journal of Cancer, 43, 845-851. doi:10.1016/j.ejca.2006.11.016
13. Hu, J.C., Sadeghi, P., Printer-Brown, L.C., Yashar, S., & Chiu, M.W. (2007). Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. Journal of the American Academy of Dermatology, 56, 317-326. doi:10.1016/j.jaad.2006.09.005
14. Jatoi, A., Rowland, K., Sloan, J., Gross, H., Fishkin, P., & Kahanic, S. (2007). Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB) [Abstract 9906]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=33357
15. Jatoi, A., Rowland, K., Sloan, J.A., Gross, H. M, Fishkin, P.A., Kahanic, S.P.,... Loprinzi, C.L. (2008). Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes. Cancer, 113, 847-853.
16. Jonker, D.J., O'Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.J.,... Moore, M.J. (2007). Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine, 357, 2040-2048. doi:10.1056/NEJMoa071834
17. Lacouture, M.E. (2006). Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews. Cancer, 6, 803-812.
18. Lacouture, M.E., Basti, S., Patel, J., & Benson, A., III. (2006). The SERIES clinic: An interdisciplinary approach to the management of toxicities of EGFR inhibitors. Journal of Supportive Oncology, 4, 236-238.
19. Lacouture, M.E., Cotliar, J., & Mitchell, E.P. (2007). Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park), 21(11, Suppl. 5), 17-21.
20. Lacouture, M.E., & Lai, S.E. (2006). The PRIDE (Paulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. British Journal of Dermatology, 155, 852-854.
21. Lacouture, M.E., Maitland, M.L., Segaert, S., Setser, A., Baran, R, Fox, L.P.,... Trotti, A. (2010). A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer, 18, 509-522.
22. Lacouture, M.E., Mitchell, E.P., Piperdi, B., Pillai, M.V., Shearer, H., Iannotti, N.,... Yassine, M. (2010). Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28, 1351-1357. doi:10.1200/JCO.2008.21.7828
23. Lee, M.W., Seo, C.W., Kim, S.W., Yang, H.J., Lee, H.W., Choi, J.H.,... Koh, J.K. (2004). Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Dermato-Venereologica, 84, 23-26.
24. Lievre, A., Bachet, J.B., Le Corre, D., Boige, V., Landi, B., Cote, J.F.,... Laurent-Puig, P. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research, 66, 3992-3995. doi:10.1158/0008-5472.CAN-06-0191
25. Lynch, T.J., Jr., Kim, E.S., Eaby, B., Garey, J., West, D.P., & Lacouture, M.E. (2007). Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist, 12, 610-621. doi:10.1634/theoncologist.12-5-610
26. Mitchell, E.P., Perez-Soler, R., Van Cutsem, E., & Lacouture, M.E. (2007). Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park), 21(11, Suppl. 5), 4-9.
27. Molinari, E., De Quatrebarbes, J., Andre, T., & Aractingi, S. (2005). Cetuximab-induced acne. Dermatology, 211, 330-333.
28. Moore, M.J., Goldstein, D., Hamm, J., Figer, A., Hecht, J.R., Gallinger, S.,... Parulekar, W. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. Journal of Clinical Oncology, 25, 1960-1966.
29. National Cancer Institute Cancer Therapy Evaluation Program. (2011). Common Terminology Criteria for Adverse Events [v.4.0]. Retrieved from http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf
30. Oda, K., Matsuoka, Y., Funahashi, A., & Kitano, H. (2005). A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular Systems Biology, 1, 2005.0010.
31. Oishi, K. (2008). Clinical approaches to minimize rash associated with EGFR inhibitors. Oncology Nursing Forum, 35, 103-111.
32. Perez-Soler, R., Delord, J.P., Halpern, A., Kelly, K., Krueger, J., Sureda, B.M.,... Leyden, J. (2005). HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist, 10, 345-356. doi:10.1634/theoncologist.10-5-345
33. Purdom, M., & Ohinata, A. (2007). Clinical management of EGFRI dermatologic toxicities: The nursing perspective. Oncology (Williston Park), 21(11, Suppl. 5), 29-30.
34. Scope, A., Agero, A.L., Dusza, S.W., Myskowski, P.L., Lieb, J.A., Saltz, L.,... Halpern, A.C. (2007). Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. Journal of Clinical Oncology, 25, 5390-5396. doi:10.1200/JCO.2007.12.6987
35. Segaert, S., Tabernero, J., Chosidow, O., Dirschka, T., Elsner, J., Mancini, L.,... Layton, A. (2005). The management of skin reactions in patients receiving epidermal growth factor receptor targeted therapies. Journal of the German Society of Dermatology, 3, 599-606.
36. Segaert, S., & Van Cutsem, E. (2005). Clinical management of EGFRI dermatologic toxicities: The European perspective. Oncology (Williston Park), 21(11, Suppl. 5), 22-26.
37. Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S.,... Seymour, L. (2005). Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine, 353, 123-132. doi:10.1056/NEJMoa050753
38. Shu, K.Y., Kindler, H.L., Medenica, M., & Lacouture, M. (2006). Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. British Journal of Dermatology, 154, 191-192. doi:10.1111/j.1365-2133.2005.07010.x
39. Siddiqui, A.D., & Piperdi, B. (2010). KRAS mutation in colon cancer: Annals of Surgical Oncology, 17, 1168-1176.
40. Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B.,... Amado, R.G. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology, 25, 1658-1664.
41. Wagner, L.I., & Lacouture, M.E. (2007). Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park), 21(11, Suppl. 5), 34-36.
42. Witherspoon, J.N., Wagner, L., & Rademaker, A. (2008). Correlation of patient characteristics and NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grading with dermatology-related quality of life (QOL) in patients with EGFR inhibitor-induced rash [Abstract 9559]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35365
43. Yarden, Y., & Sliwkowski, M.X. (2001). Untangling the ErbB signaling network. Nature Reviews. Molecular Cell Biology, 2, 127-137.